First N.Z. Prostate Cancer Patient Treated With SpaceOAR Technology

First N.Z. Prostate Cancer Patient Treated With SpaceOAR Technology
New Zealand's Kathleen Kilgour Centre (KKC) has treated the country's first patient  with Augmenix's SpaceOAR system, a medical device that protects men from rectal complications after prostate cancer radiation therapy. Because the prostate and the rectum are anatomically adjacent, radiation therapy targeting the prostate can injure the rectum and cause pain, discomfort or diarrhea. The SpaceOAR system works by injecting an hydrogel into the space between the prostate and the rectum, generating a pressure force that pushes the organs further away from each other. As a result, during prostate radiation therapy, the rectum is out of the region affected by radiation and suffers less damage. “KKC is dedicated to providing the best care for our patients and the introduction of SpaceOAR hydrogel for men with prostate cancer is yet another step in achieving this," Dr. Leanne Tyrie, the KKC's clinical director, said in a press release. "The significant decrease in bowel, urinary and sexual side effects following radiotherapy when SpaceOAR hydrogel is utilized made our decision to incorporate it as part of standard of care for prostate cancer patients very easy." Besides increasing protection to the rectum, the hydrogel can also decrease radiation's harmful side effects to urinary and sexual organs. The hydrogel maintains spacing for three months and then gradually becomes a liquid which is cleared in urine through renal filtration abou six months after injection. “Recent clinical data show that SpaceOAR hydrogel helps to significantly reduce the risk of rectal and urinary side effects and loss of sexual function associated with radiation therapy in the treatment of prostate cancer,” said Augmenix CEO John Pedersen. “We are pleased
Subscribe or to access all post and page content.